Sustained virological response by direct‑acting antivirals reduces the recurrence risk of hepatitis C‑related hepatocellular carcinoma after curative treatment
Open Access
- 29 November 2019
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 12 (2) , 111-116
Abstract
The present study aimed to assess the suppressive effect of direct‑acting antivirals (DAAs) on hepatocellular carcinoma (HCC) recurrence following curative treatment, particularly compared with interferon (IFN)‑based therapy. Among 117 curative cases of HCV‑related initial HCC between 2006 and 2017 at Gifu University Hospital, 13 and 14 cases achieved a sustained virological response (SVR) by DAA‑ (DAA group) or IFN‑based therapies (IFN group), and 64 cases were not treated with any antiviral therapy (non‑treatment group). Recurrence‑free survival (RFS) following curative treatment in each group was analyzed using the Kaplan‑Meier method and log‑rank test. A Cox proportional hazards model was used to analyze the factors that affected RFS. Age was significantly lower and serum alanine aminotransferase level was significantly higher in the IFN group than in both the DAA and non‑treatment groups. There was a significant difference in RFS between the non‑treatment group and antiviral therapy groups, including the DAA (P=0.014) and IFN groups (P=0.009); however, no significant difference was identified in RFS between the DAA and IFN groups (P=0.564). SVR achieved by DAA [P=0.011; hazard ratio (HR), 0.222; 95% CI, 0.069‑0.758] or IFN therapy (P=0.007; HR, 0.327; 95% CI, 0.145‑0.742) was an independent factor for the prevention of HCC recurrence. SVR by DAA therapy exhibited an anti‑liver tumorigenesis effect equal to that of IFN‑based therapy and reduced the risk of HCC recurrence.Keywords
This publication has 33 references indexed in Scilit:
- Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic FactorsAmerican Journal of Gastroenterology, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatmentJournal of Clinical Biochemistry and Nutrition, 2011
- Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus‐positive patients: A prospective, case series studyHepatology Research, 2010
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2002
- Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: Survey of 414 patients from four countriesJournal of Medical Virology, 2002
- Risk Factors for Recurring Hepatocellular Carcinoma Differ According to Infected Hepatitis Virus—An Analysis of 236 Consecutive Patients With A Single LesionHepatology, 2000
- Surgical resection for small hepatocellular carcinomaSurgery, 1996